The New Pandemic Covid-19: Treatment Options and Developments

References (48)

1. 1 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [DOI]
2. 2 A Novel Coronavirus from Patients with Pneumonia in China, 2019 [DOI]
3. 3 A pneumonia outbreak associated with a new coronavirus of probable bat origin [DOI]
4. 4 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [DOI]
5. 5 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [DOI]
6. 6 COVID-19: consider cytokine storm syndromes and immunosuppression [DOI]
7. 7 A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster [DOI]
8. 8 Pathological findings of COVID-19 associated with acute respiratory distress syndrome [DOI]
9. 9 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [DOI]
10. 10 First Case of 2019 Novel Coronavirus in the United States [DOI]
11. 11 The proximal origin of SARS-CoV-2 [DOI]
12. 12 Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome [DOI]
13. 13 Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus [DOI]
14. 14 SARS and MERS: recent insights into emerging coronaviruses [DOI]
15. 15 Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle [DOI]
16. 16 Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology [DOI]
17. 17 The Architecture of SARS-CoV-2 Transcriptome [DOI]
18. 18 Coronaviruses post-SARS: update on replication and pathogenesis [DOI]
19. 19 Therapeutic options for the 2019 novel coronavirus (2019-nCoV) [DOI]
20. 20 Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings [DOI]
21. 21 Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China [DOI]
22. 22 Baricitinib as potential treatment for 2019-nCoV acute respiratory disease [DOI]
23. 23 Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study [DOI]
24. 24 Tocilizumab treatment in COVID‐19: A single center experience [DOI]
25. 25 SARS: Systematic Review of Treatment Effects [DOI]
26. 26 Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase [DOI]
27. 27 Phylogenetic network analysis of SARS-CoV-2 genomes [DOI]
28. 28 Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 [DOI]
29. 29 SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway [DOI]
30. 30 Emerging coronaviruses: Genome structure, replication, and pathogenesis [DOI]
31. 31 Inhibition of SARS-CoV 3CL protease by flavonoids [DOI]
32. 32 Emerging novel coronavirus (2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments [DOI]
33. 33 Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transporters [DOI]
34. 34 Profile of Specific Antibodies to the SARS-Associated Coronavirus [DOI]
35. 35 Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2 [DOI]
36. 36 Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion [DOI]
37. 37 An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development [DOI]
38. 38 Cinanserin Is an Inhibitor of the 3C-Like Proteinase of Severe Acute Respiratory Syndrome Coronavirus and Strongly Reduces Virus Replication In Vitro [DOI]
39. 39 Withanone from Withania somnifera Attenuates SARS-CoV-2 RBD and Host ACE2 Interactions to Rescue Spike Protein Induced Pathologies in Humanized Zebrafish Model [DOI]
40. 40 CORONAVIRUS DISEASE 2019 (COVID-19) [DOI]
41. 41 Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome [DOI]
42. 42 A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [DOI]
43. 43 Hydroxychloroquine-Inhibited Dengue Virus Is Associated with Host Defense Machinery [DOI]
44. 44 Challenges of Convalescent Plasma Therapy on COVID-19 [DOI]
45. 45 Efficacy of Natural Compounds from Tinospora cordifolia Against SARS-CoV-2 Protease, Surface Glycoprotein and RNA Polymerase [DOI]
46. 46 G1-4A, a Polysaccharide from Tinospora cordifolia Inhibits the Survival of Mycobacterium tuberculosis by Modulating Host Immune Responses in TLR4 Dependent Manner [DOI]
47. 47 Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV [DOI]
48. 48 Probable Pangolin Origin of 2019-nCoV Associated with Outbreak of COVID-19 [DOI]

Cited by 5

Showing 2 of 5 known citations — external sources report more than can currently be individually listed.

Related research

• Covid-2019:“A Microbiological Monster” — shares topic coverage
• COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
• Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
• Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 — shares topic coverage
• Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia — shares topic coverage